Valeritas adds two more to board of directors
Courtesy
The V-Go, a Valeritas product, is a wearable insulin delivery device.
Over the past two weeks, New Jersey-based Valeritas, which has manufacturing, research and development operations in Shrewsbury, added two people to its board of directors.
The commercial stage medical technology company, which focuses on improving the health and quality of life for people with Type 2 diabetes, elected Peter J. Devlin and Rodney D. Altman to its board as independent directors this month. Devlin brings to the table 27 years in the medical device and in-vitro diagnostics spaces and expertise in diabetes. Altman has 16 years of venture capital, healthcare administrative and operations experience, as well as more than 25 years of clinical experience.
In February, CEO Kris Peterson announced she was stepping down to pursue other opportunities but would stay on as a consultant. John Timberlake, who was Valeritas’ president and chief commercial officer, was announced as interim CEO. At that time, the company also added three new board members from Houston healthcare-focused investment management firm CRG -- Luke Duster, Nate Hukill and Cameron Hui.
The company is expanding its independent board members.
WBJ Web Partners
Most Recent
Most Recent
0 Comments